ResMed (RMD) Reports In-Line Q4 EPS
Tweet
Share
E-mail
Get Alerts RMD Hot Sheet
Price: $221.05 -3.2%
Revenue Growth %: +6.9%
Financial Fact:
Income from operations: 94.15M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +6.9%
Financial Fact:
Income from operations: 94.15M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
ResMed (NYSE: RMD) reported Q4 EPS of $0.74, in-line with the analyst estimate of $0.74. Revenue for the quarter came in at $518.6 million versus the consensus estimate of $513.97 million.
For earnings history and earnings-related data on ResMed (RMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- UBS upgrades Lockheed Martin to Buy, sees 26% upside on missile growth
- GameStop beats second quarter estimates on collectibles
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
